Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Targeting Metabolic Disorders With Advinus Deal

This article was originally published in PharmAsia News

Executive Summary

Merck is targeting metabolic disorders in a research-based collaboration deal with Bangalore, India-based Advinus Therapeutics
Advertisement

Related Content

Advinus Bets On Novel Glucokinase, Claiming Advantages Over Peer Compounds As It Scans For Out-licensing Deal
Advinus Bets On Novel Glucokinase, Claiming Advantages Over Peer Compounds As It Scans For Out-licensing Deal
J&J Teams With Advinus For Drug Discovery In India
J&J Teams With Advinus For Drug Discovery In India
India’s Advinus Signs On With Genzyme In Malaria Research
India’s Advinus Signs On With Genzyme In Malaria Research
Orchid To Develop Merck’s Anti-Coagulant; To Buy Majority Stake In Diakron
Orchid To Develop Merck’s Anti-Coagulant; To Buy Majority Stake In Diakron
In Search Of Risk-Sharing Partners In China, India, Pharma Says
DPP IV Inhibitor Januvia First Out Of The Gate

Topics

Advertisement
UsernamePublicRestriction

Register

SC065622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel